Burning Rock Biotech Limited

Equities

BNR

US12233L2060

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:30:00 2024-07-11 pm EDT			5-day change	1st Jan Change
6.26 ^USD	+4.68%		+2.62%	-32.69%

May. 30	Burning Rock Biotech to Work With Bayer to Increase Patient Access to Precision Cancer Medicines in China	MT
May. 30	Bayer and Burning Rock Biotech Limited Collaborates to Increase Patient Access to Precision Cancer Medicines	CI

Burning Rock Biotech Limited Provides Revenue Guidance for the Full Year 2022

May 31, 2022 at 02:32 am EDT

Burning Rock Biotech Limited provided revenue guidance for the full year 2022. For the year, company expects revenue to be approximately RMB 620 million (USD 97.8 million), implying a 22% growth over full year 2021. Given the strong first quarter business performance and assuming that the impact of COVID-19 dissipates over time in China.

Latest news about Burning Rock Biotech Limited

Burning Rock Biotech to Work With Bayer to Increase Patient Access to Precision Cancer Medicines in China	May. 30	MT
Bayer and Burning Rock Biotech Limited Collaborates to Increase Patient Access to Precision Cancer Medicines	May. 30	CI
Transcript : Burning Rock Biotech Limited, Q1 2024 Earnings Call, May 29, 2024	May. 29
Earnings Flash (BNR.L) BURNING ROCK BIOTECH Reports Q1 Revenue RMB125.6M	May. 29	MT
Burning Rock Biotech Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 29	CI
Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Revenue $75.7M	Apr. 02	MT
Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts FY23 Loss $-0.90	Apr. 02	MT
Transcript : Burning Rock Biotech Limited, Q4 2023 Earnings Call, Mar 29, 2024	Mar. 29
Burning Rock Biotech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 28	CI
Earnings Flash (BNR) BURNING ROCK BIOTECH LIMITED Posts Q4 Revenue RMB121.1M	Mar. 28	MT
Burning Rock Biotech Receives Nasdaq Listing Requirement Notice	Jan. 04	MT
Burning Rock Biotech Gets Non-Compliance Notice From Nasdaq	Jan. 04	MT
Transcript : Burning Rock Biotech Limited, Q3 2023 Earnings Call, Nov 30, 2023	Nov. 30
MORNING BID AMERICAS-November bids adieu with inflation data, OPEC	Nov. 30	RE
Burning Rock Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
Burning Rock, Boehringer Ingelheim Unveil Agreement Targeting Oncology Companion Diagnostics	23-10-30	MT
Burning Rock and Boehringer Ingelheim Achieves Master Service Agreement in Oncology Companion Diagnostics	23-10-30	CI
Burning Rock Biotech Receives Breakthrough Device Designation in China for Multi-cancer Test	23-10-16	MT
Burning Rock Biotech Limited Receives Breakthrough Device Designation from China?s NMPA for its Multi-Cancer Early Detection Test	23-10-15	CI
Sector Update: Health Care Stocks Lean Lower Premarket Friday	23-09-08	MT
Burning Rock Biotech's CanCatch Product Shows 'Superior' Performance in Clinical Study as Potential Testing Tool for Lung Cancer	23-09-08	MT
Transcript : Burning Rock Biotech Limited, Q2 2023 Earnings Call, Aug 31, 2023	23-08-31
Earnings Flash (BNR.L) BURNING ROCK BIOTECH Reports H1 Revenue RMB288.8M	23-08-31	MT
Earnings Flash (BNR.L) BURNING ROCK BIOTECH Posts H1 Loss RMB-3.09	23-08-31	MT
Burning Rock Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI

Chart Burning Rock Biotech Limited

Duration

Period

More charts

Company Profile

Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.

Sector

Healthcare Facilities & Services

Calendar

2024-08-27 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
BURNING ROCK BIOTECH LIMITED	-32.69%	64.22M
SONIC HEALTHCARE LIMITED	-18.02%	8.58B
RADNET, INC.	+76.62%	4.54B
DR. LAL PATHLABS LIMITED	+14.48%	2.94B
SYNLAB AG	-3.15%	2.65B
NEOGENOMICS, INC.	-8.59%	1.89B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-53.65%	1.86B
METROPOLIS HEALTHCARE LIMITED	+22.37%	1.26B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-46.33%	1.09B
VIJAYA DIAGNOSTIC CENTRE LIMITED	+16.04%	963M

Medical & Diagnostic Laboratories